ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Hot Features

Registration Strip Icon for default Registrieren Sie sich kostenlos, um Echtzeitkurse, interaktive Charts, Live-Optionsfluss und mehr zu erhalten.

SBFM Sunshine Biopharma Inc

0,8315
-0,006 (-0,72%)
Vor Marktöffnung
Zuletzt aktualisiert: 10:18:10
Verzögert um 15 Minuten
Name Symbol Markt Aktientyp
Sunshine Biopharma Inc SBFM NASDAQ Common Stock
  Änderung Änderung % Aktuell Zeit
-0,006 -0,72% 0,8315 10:18:10
Handelsbeginn Niedrig Hoch Schlusskurs Handelsende
0,8375
more quote information »

Aktuelle News

Datum Zeit Quelle Überschrift
06.3.202422:05EDGAR2Form 8-K - Current report
05.3.202422:37EDGAR2Form PRE 14C - Other preliminary information statements
05.3.202422:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
23.2.202422:03EDGAR2Form SC 13G - Statement of acquisition of beneficial..
21.2.202422:28EDGAR2Form SC 13G - Statement of acquisition of beneficial..
21.2.202414:24EDGAR2Form PRE 14C - Other preliminary information statements
16.2.202423:01EDGAR2Form 8-K - Current report
15.2.202417:39EDGAR2Form 8-K - Current report
14.2.202421:53EDGAR2Form SC 13G - Statement of acquisition of beneficial..
14.2.202417:18EDGAR2Form 424B4 - Prospectus [Rule 424(b)(4)]
13.2.202406:15EDGAR2Form EFFECT - Notice of Effectiveness
12.2.202422:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
12.2.202415:04EDGAR2Form 8-K - Current report
09.2.202423:17EDGAR2Form S-1/A - General form for registration of securities..
01.2.202422:17EDGAR2Form S-1 - General form for registration of securities under..
30.1.202418:38EDGAR2Form 8-K - Current report
08.1.202414:10EDGAR2Form S-8 - Securities to be offered to employees in employee..
07.12.202322:59EDGAR2Form 8-K - Current report
04.12.202314:30GLOBESunshine Biopharma Moves Principal Office to New York City
13.11.202315:00EDGAR2Form 8-K - Current report
13.11.202314:00EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
02.11.202317:18EDGAR2Form 8-K - Current report
20.10.202319:06EDGAR2Form 8-K - Current report
19.10.202318:10EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
18.10.202319:32EDGAR2Form DEF 14A - Other definitive proxy statements
13.10.202316:44EDGAR2Form 8-K - Current report
05.9.202322:20EDGAR2Form DEF 14A - Other definitive proxy statements
25.8.202321:16EDGAR2Form PRE 14A - Other preliminary proxy statements
11.8.202315:00EDGAR2Form 8-K - Current report
11.8.202314:30GLOBESunshine Biopharma Reports 2023 Second Quarter Results:..
10.8.202323:03EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
16.5.202315:58GLOBESunshine Biopharma Announces Closing of $5.0 Million Private..
12.5.202314:00GLOBESunshine Biopharma Announces Pricing of $5.0 Million Private..
11.5.202315:00GLOBESunshine Biopharma Reports 2023 First Quarter..

Kürzlich von Ihnen besucht

Delayed Upgrade Clock